NEW YORK ( TheStreet) -- Shares of Pharmaceutical Product Development (Nasdaq: PPDI) have taken a tremendous swing upward. The stock is trading at $32.22 as of 10:06 a.m. ET, 25.6% above Friday's closing price of $25.66. Volume is at 5.7 million, 3.7 times the daily average of 1.5 million. Pharmaceutical Product Development has a market cap of $3 billion and is part of the health care sector and health services industry. Shares are down 5.5% year to date as of the close of trading on Friday. Pharmaceutical Product Development, Inc., a contract research organization, provides drug discovery, development, and lifecycle management services. It operates in two segments, Clinical Development Services and Laboratory Services. The company has a P/E ratio of 41.6, above the average health services industry P/E ratio of 18.2 and above the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates Pharmaceutical Product Development as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, reasonable valuation levels and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full Pharmaceutical Product Development Ratings Report. See our top % gaining stocks list for other stocks that are soaring today, or get investment ideas from our investment research center. Interested in other stocks that are soaring? Get free SMS text alerts sent to you when the action happens by texting SOAR to 95370 or select from multiple alert options.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Markets
Fiat Chrysler Automobiles Pitches Merger to Renault
Groupe Renault confirmed overnight that it has a proposal from Fiat Chrysler Automobiles for a "potential 50/50 merger."
Teva Settles With Oklahoma Over Opioid Allegations
Israeli drugmaker says its payment of $85 million to the state is not an admission of wrongdoing.
Buy Alibaba Shares on the Dip, Says Stifel, Adding It to Select List
Stifel says long-term trends working in Alibaba's favor are more significant than the trade war between the U.S. and China.
Apple Has a More Pressing Risk Than U.S.-China Tariffs, Analyst Says
The real danger is that Chinese demand for Apple products will slump, according to Dan Ives.
Legg Mason to Cut 120 Jobs as Reality Bites With Activist Peltz on Board
An announcement on job cuts comes just days after legendary corporate raider Nelson Peltz and his investment firm, Trian Fund Management, won two seats on Legg Mason's board of directors.